Esperion Therapeutics, Inc. (ESPR): PT Raised News

ESPR – JMP Securities raises PT to $153 from $60. This new price target represents a 100.55% upside over the stock’s previous closing price of $76.29.


Update: As of Dec. 14, 2018, this bullish analyst call has returned -37.12%.


Key Facts Surrounding This News Item


  • ESPR had a POWR Rating of B (Buy) coming into today.
  • ESPR was -2.95% below its 10-Day Moving Average coming into today.
  • ESPR was 1.52% above its 20-Day Moving Average coming into today.
  • ESPR was 5.69% above its 50-Day Moving Average coming into today.
  • ESPR was 22.32% above its 100-Day Moving Average coming into today.
  • ESPR was 41.42% above its 200-Day Moving Average coming into today.
  • ESPR had returned +15.87% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Esperion Therapeutics, Inc. (ESPR)


Esperion Therapeutics is focused on developing and commercializing first-in-class, oral, LDL-cholesterol-lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. The company was founded in 1998 and is based in Ann Arbor, Michigan. View our full ESPR ticker page with ratings, news, and more.

ESPR at a Glance

ESPR Current POWR Rating™
Overall POWR Rating™
ESPR Current Price $47.97 5.85%
More ESPR Ratings, Data, and News

ESPR Price Reaction

The day of this event (Mar. 8, 2018)
ESPR Closing Price$73.14 4.13%
ESPR Volume810,200
15.36% from avg
Leading up to this event
ESPR 1-mo return13.61%
After this event
ESPR 1-day return1.37%
ESPR 3-day return2.23%
ESPR 5-day return1.60%

ESPR Price Chart


The Top Stocks For 2019

More Esperion Therapeutics, Inc. (ESPR) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ESPR News
Page generated in 0.7156 seconds.